Preclinical protocols vary widely in dose, species, and tissue target
How they work: They mimic the gut hormone GLP-1, which stimulates insulin release in response to food, suppresses glucagon, slows gastric emptying, and reduces appetite
A small percentage of participants in clinical trials developed new or worsening retinopathy, making pancreatitis and retinopathy significant concerns for some users
The trust profile differentiates BrightMeds
Your body has to adjust to the digestive changes that are happening, so it is important to give it the kind of food that works with those changes, and not against them
Since this extra boost of GLP-1 and PYY occurs hours after you eat, it can tamp down cravings between meals and even the overall desire to eat the next meal